| 2025 |
Plakhova, N., Panagopoulos, V., Cantley, M. D., Trainor, L. J., Hewett, D. R., Clark, K. C., . . . Vandyke, K. (2025). Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma: MULTIPLE MYELOMA, GAMMOPATHIES. Leukemia, 12 pages.
DOI |
| 2024 |
Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Wallington-Gates, C. T., Spencer, A., . . . Zannettino, A. C. W. (2024). Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines. Leukemia Research, 139, 107469-1-107469-8.
DOI Scopus3 Europe PMC3 |
| 2023 |
Williams, C. M. D., Noll, J. E., Bradey, A. L., Duggan, J., Wilczek, V. J., Masavuli, M. G., . . . Panagopoulos, V. (2023). Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma. British Journal of Haematology, 203(4), 614-624.
DOI Scopus2 Europe PMC3 |
| 2020 |
Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., . . . Zannettino, A. C. W. (2020). GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.. PLoS One, 15(1), e0228408.
DOI WoS2 Europe PMC2 |
| 2020 |
Cheong, C. M., Mrozik, K. M., Hewett, D. R., Bell, E., Panagopoulos, V., Noll, J. E., . . . Vandyke, K. (2020). Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. Cancer letters, 475, 99-108.
DOI Scopus25 WoS20 Europe PMC21 |
| 2020 |
Friend, N., Noll, J. E., Opperman, K. S., Clark, K. C., Mrozik, K. M., Vandyke, K., . . . Zannettino, A. C. W. (2020). GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS ONE, 15(1), e0228423.
DOI Scopus3 |
| 2020 |
Mrozik, K. M., Cheong, C. M., Hewett, D. R., Noll, J. E., Opperman, K. S., Adwal, A., . . . Zannettino, A. C. W. (2020). LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.. FASEB Bioadv, 2(6), 339-353.
DOI Scopus5 WoS3 Europe PMC8 |
| 2020 |
Clark, K. C., Hewett, D. R., Panagopoulos, V., Plakhova, N., Opperman, K. S., Bradey, A. L., . . . Zannettino, A. C. W. (2020). Targeted disruption of bone marrow stromal cell-derived Gremlin1 limits multiple myeloma disease progression in vivo. Cancers, 12(8), 2149-1-2149-20.
DOI Scopus10 WoS5 Europe PMC8 |
| 2020 |
Friend, N. L., Hewett, D. R., Panagopoulos, V., Noll, J. E., Vandyke, K., Mrozik, K. M., . . . Zannettino, A. C. W. (2020). Characterization of the role of Samsn1 loss in multiple myeloma development. FASEB BioAdvances, 2(9), 554-572.
DOI Scopus7 WoS1 Europe PMC6 |
| 2020 |
Zeissig, M. N., Hewett, D. R., Panagopoulos, V., Mrozik, K. M., To, L. B., Croucher, P. I., . . . Vandyke, K. (2020). Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica, 106(12), 3176-3187.
DOI Scopus19 WoS8 Europe PMC15 |
| 2019 |
Khoo, W. H., Ledergor, G., Weiner, A., Roden, D. L., Terry, R. L., McDonald, M. M., . . . Croucher, P. I. (2019). A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 134(1), 30-43.
DOI Scopus107 WoS73 Europe PMC89 |
| 2019 |
Opperman, K. S., Vandyke, K., Clark, K. C., Coulter, E. A., Hewett, D. R., Mrozik, K. M., . . . Zannettino, A. C. (2019). Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo. Neoplasia, 21(8), 777-787.
DOI Scopus60 WoS44 Europe PMC47 |
| 2019 |
Dutta, A., Fink, J., Grady, J., Morgan, G., Mullighan, C., To, L., . . . Zannettino, A. (2019). Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia, 33(2), 457-468.
DOI Scopus93 WoS77 Europe PMC82 |
| 2018 |
Dutta, A. K., Hewett, D. R., Fink, J. L., & Zannettino, A. C. W. (2018). Using genomics to better define high-risk MGUS/SMM patients. Oncotarget, 9(93), 36549-36550.
DOI Scopus2 Europe PMC1 |
| 2017 |
Wallington-Beddoe, C., Bennett, M., Vandyke, K., Davies, L., Zebol, J., Moretti, P., . . . Pitson, S. (2017). Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 8(27), 43602-43616.
DOI Scopus41 WoS34 Europe PMC30 |
| 2017 |
Dutta, A., Hewett, D., Fink, J., Grady, J., & Zannettino, A. (2017). Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. British Journal of Haematology, 178(2), 196-208.
DOI Scopus17 WoS14 Europe PMC13 |
| 2017 |
Vandyke, K., Zeissig, M., Hewett, D., Martin, S., Mrozik, K., Cheong, C., . . . Zannettino, A. (2017). HIF-2α promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12/CXCR4 and CCR1. Cancer Research, 77(20), 5452-5463.
DOI Scopus45 WoS37 Europe PMC36 |
| 2017 |
Hewett, D., Vandyke, K., Lawrence, D., Friend, N., Noll, J., Geoghegan, J., . . . Zannettino, A. (2017). DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment. Neoplasia : An International Journal for Oncology Research, 19(12), 972-981.
DOI Scopus17 WoS12 Europe PMC14 |
| 2015 |
Cheong, C., Chow, A., Fitter, S., Hewett, D., Martin, S., Williams, S., . . . Vandyke, K. (2015). Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 332(1), 24-38.
DOI Scopus32 WoS26 Europe PMC28 |
| 2015 |
Mrozik, K., Cheong, C., Hewett, D., Chow, A., Blaschuk, O., Zannettino, A., & Vandyke, K. (2015). Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. British Journal of Haematology, 171(3), 387-399.
DOI Scopus30 WoS22 Europe PMC27 |
| 2015 |
Noll, J., Vandyke, K., Hewett, D., Mrozik, K., Bala, R., Williams, S., . . . Zannettino, A. (2015). PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 8(1), 106-1-106-16.
DOI Scopus33 WoS25 Europe PMC30 |
| 2014 |
Noll, J., Hewett, D., Williams, S., Vandyke, K., Kok, C., To, L., & Zannettino, A. (2014). SAMSN1 is a tumor suppressor gene in multiple myeloma. Neoplasia, 16(7), 572-585.
DOI Scopus40 WoS31 Europe PMC38 |
| 2010 |
Melo, J. V., & Hewett, D. R. (2010). Wrapping BCR-ABL: It's in the bag. Blood, 116(18), 3382-3383.
DOI Scopus2 |
| 2010 |
Barlow, J., Drynan, L., Hewett, D., Holmes, L., Lorenzo-Abalde, S., Lane, A., . . . McKenzie, A. (2010). A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nature Medicine, 16(1), 59-66.
DOI Scopus302 Europe PMC240 |
| 2008 |
Hiwase, D., Saunders, V., Hewett, D., Frede, A., Zrim, S., Dang, P., . . . White, D. (2008). Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research, 14(12), 3881-3888.
DOI Scopus168 WoS145 Europe PMC134 |
| 2006 |
Fallon, P. G., Ballantyne, S. J., Mangan, N. E., Barlow, J. L., Dasvarma, A., Hewett, D. R., . . . McKenzie, A. N. J. (2006). Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. Journal of Experimental Medicine, 203(4), 1105-1116.
DOI Scopus632 Europe PMC523 |
| 2005 |
Hewett, D. R., Simons, A. L., Mangan, N. E., Jolin, H. E., Green, S. M., Fallon, P. G., & McKenzie, A. N. J. (2005). Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. Human Molecular Genetics, 14(2), 335-346.
DOI Scopus81 Europe PMC58 |
| 2002 |
Hewett, D., Samuelsson, L., Polding, J., Enlund, F., Smart, D., Cantone, K., . . . Purvis, I. (2002). Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics, 79(3), 305-314.
DOI Scopus98 Europe PMC66 |
| 2002 |
Maniatis, N., Collins, A., Xu, C. F., McCarthy, L. C., Hewett, D. R., Tapper, W., . . . Morton, N. E. (2002). The first linkage disequilibrium (LD) maps: Delineation of hot and cold blocks by diplotype analysis. Proceedings of the National Academy of Sciences of the United States of America, 99(4), 2228-2233.
DOI Scopus148 Europe PMC123 |
| 2001 |
McCarthy, L. C., Hosford, D. A., Riley, J. H., Bird, M. I., White, N. J., Hewett, D. R., . . . Purvis, I. J. (2001). Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics, 78(3), 135-149.
DOI Scopus121 Europe PMC94 |
| 2001 |
McCarthy, L. C., Hosford, D. A., Riley, J. H., Bird, M. I., White, N. J., Hewett, D. R., . . . Purvis, I. J. (2001). Erratum: Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine (Genomics (2001) 78 (135-149)). Genomics, 79(2), 271.
DOI |
| 1998 |
Hewett, D., Handt, O., Hobson, L., Mangelsdorf, M., Eyre, H., Baker, E., . . . Richards, R. (1998). FRA10B structure reveals common elements in repeat expansion and chromosomal fragile site genesis. Molecular Cell, 1(6), 773-781.
DOI Scopus82 WoS76 Europe PMC58 |
| 1997 |
Yu, S., Mangelsdorf, M., Hewett, D., Hobson, L., Baker, E., Eyre, H., . . . Richards, R. (1997). Human chromosomal fragile site FRA16B is an amplified AT-rich minisatellite repeat. Cell, 88(3), 367-374.
DOI Scopus177 WoS162 Europe PMC117 |
| 1997 |
Horwitz, M., Benson, K., Li, F. Q., Wolff, J., Leppert, M., Hobson, L., . . . Raskind, W. (1997). Genetics heterogeneity in familial acute myelogenous leukemia: Evidence for a second locus at chromosome 16q21-23.2. American Journal of Human Genetics, 61(4), 873-881.
DOI Scopus40 WoS34 Europe PMC27 |
